Which Biomarkers Are Effective for Identifying Th2-Driven Inflammation in Asthma?

Zuzana Diamant*, Ellen Tufvesson, Leif Bjermer

*Bijbehorende auteur voor dit werk

    Onderzoeksoutput: Review articleAcademicpeer review

    10 Citaten (Scopus)

    Samenvatting

    Recognition of asthma as a heterogeneous disease revealed different potential molecular targets and urged the development of targeted, customized treatment modalities. Evidence was provided for different inflammatory subsets of asthma and more recently, further refined to T helper (Th)2-high and Th2-low subphenotypes with different responsiveness to standard and targeted pharmacotherapy. Given these differences in immunology and pathophysiology, proof of concept studies of novel treatment modalities for asthma should be performed in adequate, well-defined phenotypes. In this review, we describe both existing and novel biomarkers of Th2-inflammation in asthma that can be applied to classify asthma subphenotypes in clinical studies and for treatment monitoring.

    Originele taal-2English
    Pagina's (van-tot)477-486
    Aantal pagina's10
    TijdschriftCurrent Allergy and Asthma Reports
    Volume13
    Nummer van het tijdschrift5
    DOI's
    StatusPublished - okt-2013

    Citeer dit